Delphia Therapeutics

Delphia was built on paradigm-shifting insights about the evolutionary pressures that underlie cancer. We’re the first cancer company of our kind, pursuing cancer’s surprising vulnerability to oncogene overactivation, and applying these foundational insights to pioneer a whole new class of #cancer medicines requires curiosity, creativity, and good old-fashioned truth-seeking science. We recently held a founder’s meeting, where co-founders Michael D., William Sellers, and CEO Kevin Marks got together with the team to discuss exciting new results and brainstorm future steps. We’re grateful for our founders’ commitment to our mission and their dedication to finding new ways to tackle cancer. 

Happy #EmployeeAppreciationDay! At Delphia, we believe the sum of the whole is greater than its parts. Each of our team members contribute to our culture of authenticity, inclusivity, and relentless drive to help patients and their families. Thank you for your incredible commitment to our work, Delphia team!

In the latest episode of BioSpace's The Weekly, CEO Kevin Marks sat down with Annalee Armstrong to discuss Delphia's recent feature on the NextGen Class of 2025, our pioneering of #activationlethality, and the path to our 2024 Series A financing. Tune in for more insight on how we are igniting a new field of #cancer therapeutics. https://lnkd.in/gnUMpTHW

#DYK most targeted #oncology therapies often have short-lived efficacy due once the body develops resistance? That's why Delphia is focused on developing innovative therapies that anticipate and overcome resistance through #activationlethality, aiming for deeper and longer-lasting responses for patients. Activation lethality offers the potential for new cancer medicines that are effective on their own, while also combating the rapid emergence of resistance to existing targeted therapies. Learn more about our next-gen approach to cancer on our website. www.delphiatx.com/science

International Day of Women and Girls in Science marks a day of celebration for the outstanding #womeninbiotech who are driving progress, breaking barriers, and shaping the future. Science thrives when diverse voices and perspectives come together to push boundaries. At Delphia, we believe representation matters. Today, we're elevating the voices of women at Delphia and their experiences as women in #STEM. Click below to read more.

What if, instead of inhibiting #cancer genes, we pushed them into overdrive? That's the question that sparked the launch of Delphia, and it landed us on Boston Business Journal's Startups to Watch in 2025. At Delphia, we’re redefining cancer treatment with #activationlethality, a next-generation precision approach that targets cancer’s surprising vulnerability to oncogene overactivation. While most treatments aim to block these genes, we take the opposite approach—overactivating them to trigger cancer’s self-destruction. We're excited to continue executing our mission throughout this year. Check out the full list. https://lnkd.in/d5GscFaR

Cancer is more than just a disease - it's a life-altering diagnosis for both patients and their loved ones. For us, cancer is personal. Our commitment to developing more effective medicines for cancer is personal. At Delphia, we are committed not only to making new cancer treatments but to reshaping the standard of care for patients. Members of our team share what #WorldCancerDay means to them below.

At Delphia, our #2025 strategy isn't just tied to one year, rather, it's a long-term vision of approaching cancer biology from a new perspective by leveraging activation lethality. President and CEO Kevin Marks shares his perspective on the continuous evolution and growth of our mission to helping patients and their families in a new way.

Our team members are not strangers to the effort it takes to build and deliver meaningful treatments for people living with #cancer. The support our team's families provide is an essential part of Delphia's success. We're grateful for the selflessness of all those a part of our mission, and we enjoyed spending time with the extended team over our winter celebration.

As the BioSpace team put it, though activation lethality may sound "straight out of a spy novel," it's actually the name of our next-generation approach to a new wave of cancer therapeutics. We're honored to kick off 2025 by being named to BioSpace's NextGen: Class of 2025, a list of the hottest new life sciences companies in the U.S. This recognition is a testament to the dedication of our talented scientists and company builders. https://lnkd.in/e838FJrV